Evidence-based disease management in medication-use evaluation: application to drotrecogin alfa (activated) in severe sepsis.
Durthaler
Jeffrey M
JM
Outcomes Research, U.S. Medical Division, Eli Lilly and Company, Indianapolis, IN 46285, USA. durthaler_jeffrey_m@lilly.com
Ernst
Frank R
FR
D000890:Anti-Infective Agents / Q000191:economics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D017723:Drug Utilization Review; D019317:Evidence-Based Medicine; D005569:Formularies as Topic; D017048:Health Care Costs; D006801:Humans; D017410:Practice Guidelines as Topic; D011486:Protein C / Q000191:economics / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000191:economics / Q000627:therapeutic use; D018401:Sample Size; D018805:Sepsis / Q000188:drug therapy* / Q000191:economics; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated